文献速递妇科

帕博利珠单抗联合或不联合贝伐珠单抗治疗复发性或转移性宫颈癌的成本效果分析

Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis.
PubMed 文献 · Gynecol Oncol · 2022-04-12

本研究采用决策分析模型,基于KEYNOTE-826数据估算质量调整生命年,比较化疗联合帕博利珠单抗及贝伐珠单抗(CPB)、化疗联合帕博利珠单抗(CP)与化疗联合贝伐珠单抗(CB)在复发性或转移性宫颈癌中的成本效果。结果显示CP相对CB的增量成本效果比为92,678美元/QALY,低于100,000美元/QALY的支付意愿阈值;CPB被支配。模型限于PD-L1阳性肿瘤时CP的ICER改善至63,670美元/QALY。

要点

  • CP相对CB的ICER为92,678美元/QALY,低于100,000美元/QALY的支付意愿阈值。
  • CPB被支配,需帕博利珠单抗每周期费用大幅下降才可能具有成本效果。
  • 模型限于PD-L1阳性肿瘤时,CP相对CB的ICER改善至63,670美元/QALY。

核心结论

  • CP相对CB在复发性或转移性宫颈癌中具有成本效果。
  • CPB需疗效远超CB和CP才具有成本效果。
  • 模型限于PD-L1阳性肿瘤时,CP相对CB的ICER改善约30,000美元/QALY。

研究设计与样本

  • 决策分析模型,数据来自KEYNOTE-826,用于估算质量调整生命年(QALY)。
  • 药物成本采用平均批发价估算。
  • 计算增量成本效果比(ICER),支付意愿阈值设为100,000美元/QALY。
  • 对含帕博利珠单抗方案的成本和效果进行敏感性分析。

主要发现

  • 相对CB,CP的ICER为92,678美元/QALY。
  • CPB被支配。
  • 若CP的总生存期从24.4个月降至23.4个月,ICER将超过支付意愿阈值。
  • 若假设CP的总生存期为20.4个月,ICER增至187,746美元/QALY。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the cost-effectiveness of the addition of pembrolizumab in various combinations in patients with recurrent/metastatic cervical cancer. METHODS: A decision-analysis model evaluated the cost-effectiveness of chemotherapy plus pembrolizumab and bevacizumab (CPB) relative to chemotherapy plus pembrolizumab (CP) and chemotherapy plus bevacizumab (CB) in cervical cancer patients. Data from KEYNOTE-826 was used to estimate quality-adjusted life-years (QALYs). Drug cost estimates were obtained using average wholesale prices. Incremental cost-effectiveness ratios (ICERs) were calculated to determine cost/QALY. The willingness-to-pay threshold (WTP) was set a $100,000/QALY. Sensitivity analyses were performed on cost and effectiveness for pembrolizumab-containing regimens. RESULTS: Cost of treatment with CB, CP, and CPB were $416 million (M), $713 M, and $1.51 billion, respectively. Relative to CB, the ICER for CP was $92,678. CPB was dominated. Sensitivity analyses were performed varying the cost and efficacy of CP and CPB. If overall survival (OS) with CP decreased from 24.4 months to 23.4 months, the ICER would exceed the WTP. If the OS from CP is assumed to be 20.4 months, the ICER increases to $187,746. The ICER for CP improves to $63,670 when the model is restricted to PD-L1 positive cancers. With CP eliminated, CPB becomes cost-effective relative to CB if the cost of pembrolizumab per cycle decreases from $12,080 to $2913 for the baseline model and to $4644 for the PD-L1 model. CONCLUSIONS: CP is cost-effective relative to CB for recurrent or metastatic cervical cancer. The efficacy of CPB would need to far exceed both CB and CP to be cost-effective. Restricting the model to patients with PD-L1 positive tumors dramatically improves the ICER for CP relative to CB by $30,000/QALY.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Barrington DA, Riedinger C, Haight PJ, et al. Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis. Gynecol Oncol. 2022. PMID: 35422338. doi:10.1016/j.ygyno.2022.03.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。